Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLN-346 SAD in Healthy Volunteers
NCT04236219Phase 1Completed
- Sponsor
- Allena Pharmaceuticals, Inc.
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALLN-346 in hyperuricemia (4 arms), sponsored by Allena Pharmaceuticals, Inc. Primary endpoint: Incidence of treatment emergent adverse events at 28 days. Started Sep 2020; status: completed.
02
Drugs
ALLN-346
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on NCT04236219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04236219.